Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

NEW YORK (Reuters) -WeightWatchers will announce on Tuesday Dr. Kim Boyd as its chief medical officer, and plans for a new program to help women manage the transition into menopause and beyond, part ...

A criminal justice student who avoided a potential death sentence by pleading guilty Wednesday to the brutal stabbing deaths ...

Welcome to our live blog tracking the latest news and developments from the United States. Stay updated with real-time ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Zepbound is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for weight loss, and its key ingredient is tirzepatide. While Zepbound may be a powerful tool for ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Dubai's 13,000 food and drink establishments go all out to attract customers in one of the world's most saturated dining markets. They cater to all tastes and budgets: inexpensive biryani, ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.